OncoMatch/Clinical Trials/NCT06868485
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Is NCT06868485 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including WSD0922-FU Tablets, Dose level A and WSD0922-FU Tablets, Dose level B for non small cell lung cancer.
Treatment: WSD0922-FU Tablets, Dose level A · WSD0922-FU Tablets, Dose level B — This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: EGFR c797s
Required: EGFR mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first-line
Evidence of radiological disease progression while on a previous continuous treatment with first-line Osimertinib treatment
Cannot have received: investigational agent or other anticancer drug
Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ function as demonstrated [excluded]
Inadequate bone marrow reserve or organ function as demonstrated [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- FOMAT Oncology · Oxnard, California
- Cleveland Clinic Weston Hospital · Weston, Florida
- Karmanos Cancer Institute · Detroit, Michigan
- Hackensack Meridian Health-Southern Ocean Medical Center · Manahawkin, New Jersey
- Cleveland Clinic · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify